Objective
Colorectal cancer (CRC) represents one of the most important health problems worldwide. Decreasing the mortality rate by CRC in Europe is a clear unmet need today. Medical community agrees that this number of CRC related deaths could be prevented by adequate screening programs for early detection. European authorities look for new strategies to address the clinical need for early diagnosis of CRC that will reduce patient care associated costs. Potential savings would be achieved if CRC patients were diagnosed earlier. The objective of this proposal is to validate and commercialize a novel, non-invasive, simple to use kit (ColoFastTM), regulatory approved for the diagnosis of CRC in blood. It is based on a new generation of leading-edge biomarkers that showed very high sensitivity and specificity for early detection of CRC in two prospective cohorts. The commercialization of the kit will have clear impact in improving survival of patients and reducing mortality by CRC cancer, with significant costsavings for National Health Services. It will be easily implemented in the clinical routine of the majority of European hospitals, with better acceptance of patients. ColoFast represents a significant business opportunity, addressing a clear unmet medical need in a large and expanding target population of 189M people in Europe in 2020, growing at 25%, with a significant global market of €1,616M in Europe, the US and Japan this year. It will have a huge impact on the growth of a SME as Amadix over the next 10 years, multiplying the team size by five in five years (41 employees in 2020). 2M European people will benefit from the test in 2024. Amadix turnover in 2021 will be €18 m, which will give our company a profit of €7 m in 2021. From this year on the company will be profitable. Overall, ColoFast will reduce mortality rate and treatment cost while improving quality of life in a cost-effective way, assisting also to fulfill European priorities for healthcare improvements.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- social sciences sociology demography mortality
- natural sciences computer and information sciences databases
- medical and health sciences clinical medicine oncology colorectal cancer
- engineering and technology medical engineering medical laboratory technology laboratory samples analysis
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.3.1.3. - Treating and managing disease
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
SME-2 - SME instrument phase 2
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-SMEInst-2016-2017
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
47004 Valladolid
Spain
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.